Clinical Trial Update: Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting [Phase 4]

View source ↗

Summary

This Phase 4 trial assesses outpatient administration of Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma, including diffuse large B-cell lymphoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Large B-cell Lymphoma

Drugs mentioned

• Yescarta (axicabtagene ciloleucel)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2025-03-27